Boston Scientific Corporation (NYSE:BSX) is set to announce third quarter earning results on Wednesday 28th October 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BSX to report 3Q20 income of $ 0.25 per share.
For the full year, analysts anticipate top line of $ 10071.00 million, while looking forward to income of $ 1.01 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 11,809.00 million ~ $ 12,023.00 million, where as bottomline are predicted in a range of $ 1.74 ~ $ 1.79 per share
Click Here For More Historical Outlooks Of Boston Scientific Corporation
Previous Quarter Performance
Boston Scientific Corporation communicated income for the second quarter of $ 0.08 per share, from the revenue of $ 2,003.00 million. The quarterly earnings shrunk 79.49 percent while revenues contracted 23.87 percent compared with the same quarter last year.
Street analysts expected Boston Scientific Corporation to report loss of $ 0.02 per share on revenue of $ 1730.33 million for the second quarter. The bottom line results beat street analysts by $ 0.1 or 500.00 percent, at the same time, top line results outshined analysts by $ 272.67 million or 15.76 percent.
Stock Performance
Shares of Boston Scientific Corporation traded low $ -0.81 or -2.20 percent on Tuesday, reaching $ 36.05 with volume of 11.83 million shares. Boston Scientific Corporation has traded high as $ 36.99 and has cracked $ 36.00 on the downward trend
According to the previous trading day, closing price of $ 36.05, representing a 52.95 % increase from the 52 week low of $ 24.10 and a 20.94 % decrease over the 52 week high of $ 46.62.
The company has a market capital of $ 51.58 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 11th September 2020, initiated by Wolfe Research at Peer Perform rating, with $ 46.00 target price.
Conference Call
Boston Scientific Corporation will be hosting a conference call at 8:00 AM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bostonscientific.com
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
